PT-141 (Bremelanotide) vs Kisspeptin-10
PT-141 vs Kisspeptin for libido: melanocortin pathway vs upstream HPG axis. Two different mechanisms, different use cases.
The verdict
Two completely different routes to the same goal. PT-141 acts on the melanocortin system in the brain, it's an on-demand libido peptide and is FDA-approved (as Vyleesi) for female sexual dysfunction. Kisspeptin works further upstream, kicking off the natural GnRH to LH to testosterone cascade, so it's more about the underlying hormonal axis than a same-day effect. For acute, situational desire, PT-141 is the direct lever. For supporting the hormone cascade itself, Kisspeptin is the one that fits.
PT-141 (FDA-approved as Vyleesi) is the libido peptide. Different mechanism than Viagra, it works on desire, not just blood flow. Used as-needed, not daily. Nausea is the main side effect, especially the first few times.
Kisspeptin sits at the very top of the chain that produces testosterone. When you inject it, your body's own testosterone-making cascade fires off naturally. It's a different lever than PT-141, kisspeptin is upstream hormones, PT-141 is melanocortin pathway.
Which one should you pick?
Pick PT-141 (Bremelanotide) if users with situational or low-baseline libido or couples wanting a non-pde5-inhibitor option.
Pick Kisspeptin-10 if users with low lh / suppressed hpg axis post-cycle or fertility-adjacent contexts under medical guidance.
Still torn between PT-141 (Bremelanotide) and Kisspeptin-10?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.
Common questions
- Can you stack PT-141 (Bremelanotide) with Kisspeptin-10?
- Neither entry lists the other as a stack partner. Each full entry has its own stacking notes.
- What's the dose difference between PT-141 (Bremelanotide) and Kisspeptin-10?
- PT-141 (Bremelanotide): 1.0-1.75 mg sub-q, at least 45 min before activity (FDA Vyleesi label minimum). No more than 1 dose in 24h, no more than 8 doses per month.
- Kisspeptin-10: 25-100 mcg sub-q, 1-2x daily during short courses.
- Is PT-141 (Bremelanotide) or Kisspeptin-10 FDA approved?
- PT-141 (Bremelanotide): Approved as Vyleesi (Bremelanotide), 2019, for hypoactive sexual desire disorder in premenopausal women.
- Kisspeptin-10: Not FDA approved. In clinical investigation for fertility / HPG-axis applications.
- What are the side effects of PT-141 (Bremelanotide) vs Kisspeptin-10?
- PT-141 (Bremelanotide): Nausea (most common, severe in first uses); Facial flushing; Headache.
- Kisspeptin-10: Generally well tolerated; Mild headache rarely; Brief facial flush.
Want the latest evidence updates?
Drop your email and we'll send you the one-page checklist for vetting any peptide before you trust a vendor or a forum: what to verify, the red flags, and the questions to ask a licensed provider. No card.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.